The Efficacy and Safety of Prolonged Oral Anticoagulation for the Prevention of Thromboembolic Events in Patients Recovered From COVID-19 1 Year After Hospital Discharge: The SARCOV-19 Prospective Registry

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

(2022) Stefano Barco et al.   Lancet Haematology

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

(2021) Dimitrios Giannis et al.   BLOOD

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19

(2021) Jean M. Connors et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

(2021) Eduardo Ramacciotti et al.   LANCET

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

(2020) Julie Helms et al.   INTENSIVE CARE MEDICINE

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients

(2020) Alex C. Spyropoulos et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Thrombosis risk associated with COVID-19 infection. A scoping review

(2020) Fatimah Al-Ani et al.   THROMBOSIS RESEARCH